Helix's pivot from consumer genomics to population genomics highlights broader shifts in the human genomics landscape

July 29, 2021 | Case Study

Helix Genomics came into the spotlight a few years ago when it pioneered a digital marketplace concept for genomics where it used a dynamic consent model to allow third-party developers to turn genomics data into personalized insights for the consumer. It also offered whole-exome sequencing (WES), which spans all known protein-coding genes, and not just panel tests (with a subset of genes, typically a couple of hundred genes, tested), which typical direct-to-consumer companies offer. Both of these differentiators promised to propel the company to market leadership. However, the company has not made significant inroads into the consumer genomics business, as evidenced by its recent funding round and general shift in business strategy.

About Lux Research

Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.

Already a Lux Client?

Sign In

Interested in Learning More?

Contact us to learn the benefits of becoming a Lux member.

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 20 280 7900

For APAC (Singapore)
+65 6592-6978